These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18650259)

  • 1. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
    Guarneri V; Giovannelli S; Ficarra G; Bettelli S; Maiorana A; Piacentini F; Barbieri E; Dieci MV; D'Amico R; Jovic G; Conte P
    Oncologist; 2008 Aug; 13(8):838-44. PubMed ID: 18650259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
    Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
    Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA; Hill AG; Houssami N
    Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
    Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
    J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
    Kasami M; Uematsu T; Honda M; Yabuzaki T; Sanuki J; Uchida Y; Sugimura H
    Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
    Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
    Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
    Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases.
    Martinez SR; Young SE; Giuliano AE; Bilchik AJ
    Am J Surg; 2006 Feb; 191(2):281-3. PubMed ID: 16442961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptor status of breast cancer metastases.
    Branković-Magić M; Janković R; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):55-60. PubMed ID: 11862473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.